P21 (P021) Dosing: Studied Regimens (Preclinical)
Human schedule
Controlled data on this compound are limited. The regimens below were gathered from public sources online (studies and protocols) and are given as a reference, not a usage plan.
P21 (P021) is a derivative of the active region of CNTF; it has been studied mainly preclinically (rodents, oral in feed), while research protocols usually administer it subcutaneously (less often intranasally). The below is a generalized reference from protocols, not a clinically validated regimen.
This is a concise reference to regimens described for adults; it is not an individual prescription.
| Period / condition | Dose | Escalation |
|---|---|---|
| Start | 100–250 mcg/day, subcutaneous | Starting dose |
| Typical regimen | 250–500 mcg/day, 4–6 week course | Increase if needed |
| Upper bound cited in protocols | up to ~1000 mcg/day | Maximum in this schedule |